Particle Size News and Research

RSS

Scientists report potential toxicity of nanoparticles in consumer products

Scientists are reporting that particle size affects the toxicity of zinc oxide, a material widely used in sunscreens. Particles smaller than 100 nanometers are slightly more toxic to colon cells than conventional zinc oxide. Solid zinc oxide was more toxic than equivalent amounts of soluble zinc, and direct particle to cell contact was required to cause cell death.

25 Jun 2010

Malvern publishes online chemical imaging bibliography

By combining conventional spectroscopy with sophisticated mapping and imaging technology in its SyNIRgi chemical imaging system and ISys chemical imaging software, Malvern Panalytical has greatly extended the application of vibrational spectroscopy.

From Malvern Panalytical 3 Jun 2010

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

When loaded with an anticancer drug, a delivery system based on a novel material called nanosponge is three to five times more effective at reducing tumor growth than direct injection.

3 Jun 2010

MicroStockProfit.com releases investment report on Discovery Laboratories

MicroStockProfit.com announces an investment report featuring Discovery Laboratories Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

20 May 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they are presenting data from several studies of two investigational inhaled respiratory compounds at the annual American Thoracic Society International Conference taking place in New Orleans May 14-19, 2010. Data on aclidinium bromide, an inhaled muscarinic antagonist, which is in Phase III development for COPD, and LAS100977, a long-acting beta 2-agonist, in Phase II development for asthma, will be presented in 11 separate posters.

11 May 2010

Enzyme technology developed to improve quality, safety and nutritional attributes of oat based foods

Oats is a highly nutritious cereal, which can be tolerated by large number of celiac patients. A range of commercial oat flours as well as specific oat flours produced from single varieties have been evaluated for their suitability for bread-baking. Enzyme technology, bioprocessing as well as high-pressure processing technology have been successfully applied to improve the quality, safety and nutritional attributes of oat based foods.

5 May 2010

Potential toxicity of zinc nanoparticles in sunscreen products

8 Apr 2010

Malvern exhibits proven PAT solutions for real-time particle sizing at Interphex 2010

Interphex, April 20–22 New York, provides an excellent opportunity to learn how proven PAT (process analytical technology) solutions from Malvern are transforming the control of key unit operations such as milling.

25 Mar 2010

MicroConstants acquires access to new nanosizing technology

MicroConstants, a GLP-compliant Contract Research Organization specializing in bioanalytical and pharmacokinetic analysis, has acquired access to a new nanosizing technology that transforms water insoluble compounds into nanoparticles, making formulation preparation and dosing for toxicology studies easier.

9 Mar 2010

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week’s DNA Vaccines 2010 in New Orleans, LA concerning the formulation and topical administration of the DermaVir therapeutic vaccine for HIV/AIDS. DNA Vaccine 2010 invites leading scientists to report on the latest research in the progressive field of DNA or Genetic Vaccines.

3 Mar 2010

PARI Respiratory Equipment launches new aerosol delivery system

Today, PARI Respiratory Equipment launched their newest aerosol delivery system, the Vios. Paired with PARI's gold standard reusable nebulizers, Vios delivers fast treatments, small particle size, and high respirable drug dose to the lungs. Vios also features an extended warranty and Timestrip, an easy to use reminder for patients to replace their nebulizer every six months.

1 Mar 2010

JACI supplement supports the importance of small airways in asthma management

Increasing evidence supports the importance of small airways in the diagnosis and treatment of asthma; however, focused areas of discussion and critical review of this topic have been lacking. To foster a better understanding of the role of small airways in asthma management, Teva Respiratory, a subsidiary of Teva Pharmaceutical Industries Ltd., will be providing reprints of a special supplement entitled "Small Airway Involvement: A Key to Asthma" from the December issue of the Journal of Allergy and Clinical Immunology at their exhibit (Booth #724) at the American Academy of Allergy, Asthma & Immunology Annual Meeting being held Feb. 26-March 2, 2010 in New Orleans, La.

1 Mar 2010

Particle Sciences to acquire HORIBA's Raman/Particle Characterization System

Particle Sciences Inc., a leading pharmaceutical CRO, is adding to its formulation and characterization abilities through a cooperative agreement with HORIBA Scientific. Under the agreement Particle Sciences will acquire a HORIBA Raman/Particle Characterization System.

7 Jan 2010

New data provide comprehensive review of emerging role of small airways in asthma management

Teva Respiratory, a division of Teva Pharmaceutical Industries Ltd., today announced the publication of four articles in a special supplement of the December issue of the Journal of Allergy and Clinical Immunology (JACI), providing a comprehensive scientific review of the emerging role of the small airways in the understanding and treatment of asthma.

8 Dec 2009

Experts to discuss the patented chemical imaging technology at DDL 20 meeting

In today's fast growing inhalables market, the availability of suitable, efficient and cost-effective means of gathering particle analysis data for pulmonary formulation is clear. At this year's Drug Delivery to the Lungs 20 (DDL 20) meeting, experts from ChemImage Corporation, will be on hand to discuss our patented chemical imaging technology and how ingredient-specific particle sizing (ISPS) fulfils precisely this requirement for drug particle size data.

23 Nov 2009

Enavail obtains an exclusive license for a portfolio of particle engineering technologies

Particle engineering company Enavail announced today that it has obtained an exclusive license from The University of Texas at Austin for a portfolio of particle engineering technologies that will be utilized for pharmaceutical, biotechnology and nutraceutical applications.

10 Nov 2009

DaVita to demonstrate clinical outcomes, patient care and nutrition through 43 abstracts

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research®, today announced that company representatives will deliver 43 abstracts—40 posters and three oral presentations—at this year’s American Society of Nephrology’s (ASN) Renal Week to be held in San Diego, Calif., from Oct. 27 – Nov. 1, 2009.

24 Oct 2009

IQPC to hold the 8th Annual Polymorphism & Crystallization Scientific Forum

Organized by IQPC, the 8th Annual Polymorphism & Crystallization Scientific Forum will be held October 26-28, 2009 at the Hub Cira Center in Philadelphia, PA (www.polymorphismforum.com).

From IQPC Ltd 15 Oct 2009

New technique for tracing ultra-fine particles

Limit values for fine dust emissions are based on total particle weight. It is the ultra-fine particles, however, that are particularly harmful to health. A new technique separates them by size and identifies their composition - directly where they arise.

5 Oct 2009

Court rules in favor of Eli Lilly for Evista's method-of-use patents

The U.S. District Court for the Southern District of Indiana today upheld Eli Lilly and Company's (NYSE: LLY) method-of-use patents on Evista(R) (raloxifene HCl tablets). In the case of Eli Lilly and Company v. Teva Pharmaceuticals Industries Ltd., the court ruled in favor of Lilly on all accounts for these method-of-use patents, including the patent doctrines of obviousness, enablement, and inequitable conduct.

24 Sep 2009